Review Article
Efficacy of Alendronate for Preventing Collapse of Femoral Head in Adult Patients with Nontraumatic Osteonecrosis
Table 3
Other outcomes reported from studies evaluating efficacy of alendronate in avascular necrosis of femoral head.
| | Study | Clinical function (HHS) | Hip pain (VAS) |
Adverse effects | | Baseline | After treatment | Baseline |
After treatment | | Aln | Control | Aln | Control |
Aln |
Control |
Aln |
Control |
| | Alendronate versus control/placebo | | Chen et al. 2012 [13] | 78.1 ± 12.5; | 76.6 ± 15.2 | 79.3 ± 14.2 | 83.8 ± 12.8 | NA | NA | NA | NA | None |
| | Lai et al. 2005 [14] | 67.6 (26–88); | 65.7 (34–84) | 74.4 ± 7.8; | 49.2 ± 9.2 | NA | NA | NA | NA | NA |
| | Nishii et al. 2006 [15] | NA | NA | NA | NA | NA | NA | NA | Aln versus control unchanged: 15 versus 6, improved: 4 versus 0, worsened: 1 versus 7 () | Allergy and abdominal discomfort: 2 |
| | Alendronate + ESWT versus ESWT alone | | Hsu et al. 2010 [31] | 74.5 ± 10.8; | 77.2 ± 14.5 | 87.8 ± 8.4 | 90.8 ± 12.9 | 5.4 ± 2.2 | 5.4 ± 2.0 | 1.5 ± 1.3; | 1.1 ± 1.5 | Dyspeptic symptoms: 3 |
| | Wang et al. 2008 [32] | 79.2 ± 12.9; | 75.1 ± 6.1 | 95.3 ± 8.0; | 94.3 ± 4.5 | 5.03 ± 2.75; | 5.97 ± 2.30 | 0.69 ± 1.19; | 0.6 ± 1.06 | None |
|
|
Aln: alendronate; ESWT: extracorporeal shockwave treatment; HHS: Harrris hip score; VAS: visual analog scale; NA: not available.
|
